Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001208751 | SCV001380157 | uncertain significance | Diffuse cerebral and cerebellar atrophy - intractable seizures - progressive microcephaly syndrome | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 538 of the QARS protein (p.Arg538Gln). This variant is present in population databases (rs778807845, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with QARS-related conditions. ClinVar contains an entry for this variant (Variation ID: 813576). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001563017 | SCV001785883 | uncertain significance | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25471517) |
Ambry Genetics | RCV002549245 | SCV003723951 | uncertain significance | Inborn genetic diseases | 2022-07-26 | criteria provided, single submitter | clinical testing | The c.1613G>A (p.R538Q) alteration is located in exon 17 (coding exon 17) of the QARS gene. This alteration results from a G to A substitution at nucleotide position 1613, causing the arginine (R) at amino acid position 538 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Department of Pediatrics, |
RCV001252759 | SCV001163902 | uncertain significance | Microcephaly | no assertion criteria provided | research |